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Introduction to Appalachia, Its Health Disparities, and Overall Reasons 
They Exist 
        The Appalachian Regional Commission (ARC) defines the Appalachian Region as, 
“The 205,000-square-mile region that follows the spine of the Appalachian Mountains 
from southern New York to northern Mississippi. It includes all of West Virginia and 
parts of 12 other states: Alabama, Georgia, Kentucky, Maryland, Mississippi, New York, 
North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, and Virginia.” The 
Appalachian Region is home to over 25 million people (“Appalachian Region”, 2015). 
Appalachian people hold a culture of their own, a culture that not many outsiders know 
much about. In fact, only recently, due to technology and communication improvements, 
has information about this unique culture started to emerge. Appalachia is historically 
known as a region that is lacking in healthcare and home to many unhealthy inhabitants. 
Currently, many studies are emerging, focusing on improving healthcare and 
understanding the environmental, social, and cultural distinctions in the region that may 
lead to limitations (Couto, 2012).  There are several broad factors that may contribute to 
the unhealthiness of the region as a whole including poverty, rurality, and the various 
cultures and beliefs of the region.  
        There are several factors that may lead to disparities in healthcare. One main factor 
in the lack of healthcare may be contributed to poverty. Poverty, although not evenly 
distributed throughout the region, is rampant. The ARC reports that from 2009-2013 the 
Appalachia region had a poverty rate of 17.0%, compared to the national poverty rate of 
15.4% (“Poverty Rates in Appalachia”, 2014). As stated, poverty is not universal, and is 
usually found in clusters throughout. Poverty may prevent Appalachians from seeking out 
healthcare due to affordability and even transportation costs (Couto, 2012). 
        In addition to poverty, rurality may also prevent Appalachians from receiving 
healthcare. In the past several years Appalachia has transformed from a rural to an 
urbanized region. However, there are still several areas, primarily in central Appalachia, 
that are mostly rural. Many Appalachians consider rurality a stereotype, but it is reality 
that more rural areas do not have healthcare access close by. Hospitals and doctors' 
offices are more concentrated in metro, urban areas than in rural regions of Appalachia. 
Lack of transportation and money to travel may impede the possibility of seeking a 
professional’s health advice (Couto, 2012).  
        Lastly, and more broadly, the social culture of the region may have an impact of the 
ability to receive healthcare. Appalachians are hesitant to describe their culture as a 
whole entity, as each area in the region has distinct cultural differences. They are also 
afraid that stereotypes may be derived. However, there are a few broad topics that are 
mostly true for the entire region (Couto, 2012). Appalachian people consider taking care 
of oneself and family a priority, meaning they will put taking care of the family through 
work before taking the time to visit a health professional (Gessert, 2015). It is this 
independent focus that leads to many healthcare providers to discriminate. Providers may 
be likely to lackadaisically treat the patient due to the belief the patient will not listen 
them and will disagree on the treatment (Puhl, 2010). Appalachians generally do not trust 
with ease, and are hesitant to trust people, like doctors, that live a different and more 
educated lifestyle. They may also see the help from doctors as a charity, and thus, be less 
receptive of advice (Beringer, 2006).   
        Another aspect of Appalachian social culture is family. Family plays an important 
role in the culture and health of Appalachians. The Appalachian family is more than the 
nuclear family; it includes the parents, children, grandparents, and the parents’ siblings 
and children. In a broader sense it can even include the community. Children are usually 
taken care of by grandparents and other family members instead of attending daycare 
while their parents work. This leaves the family in charge of noticing any healthcare 
ailments in the child. The family also depends on each other to raise money to attend 
healthcare visits annually. This leads back to the discussion on poverty in the family 
(Welch, 2014). The family also usually shares traditions and faith. The Appalachian 
region is known for having strong ties to religion and faith. While religion is not 
universal in the region, it does have an impact in some areas pertaining to healthcare. The 
Appalachian people are more likely to believe in faith-based fatalism, or the concept that 
illness is a part of God’s plan and He will heal the patient. This thought process might 
lead to Appalachians to believe that all illness is “in God’s hands” and medication is not 
necessary (Welch, 2011). Healthcare providers must be aware of religious beliefs in an 
area as they can drastically affect how a patient acts towards taking medication and even 
attending appointments.  
        The social, economic, and cultural aspects of the Appalachian region are very broad 
and specific to the area. It is hard to account for every factor, and even harder to 
determine which ones to include, when studying how they may impact the healthcare in a 
specific Appalachian city. Each Appalachian town must cater to its own social and 
cultural beliefs when developing a healthcare plan. Poverty, the urbanization of the area, 
and the cultural attitudes of the area are among the factors that must be accounted for. As 
stated, these are broad attitudes of the Appalachian people, and do not apply to the whole 
population. However, these attitudes are important to note as crafting a health plan to 
include them may improve communication, education, and overall health in the 
Appalachian region. 
Potential Reasons for Health Disparities in Appalachian Pediatric Patients 
        Not much is known about Appalachia as a whole, and even less is known about the 
children that reside in the region. Social scientists and healthcare providers are just 
beginning to develop systems to help the region, but not many of these developments 
focus on the health of the Appalachian child. The Appalachian lifestyle can have an 
affect on the health of youth in the region, as they are dependent on the family and the 
overall system to meet their needs. While the previously mentioned aspects of the region 
will affect everyone in the region, there are a few more characteristics of Appalachia that 
affect youth more specifically in healthcare including lack of managed care, education 
and social distance, and the social environment of the child. 
        Managed care is a health system that is designed to deliver quality health care at a 
reduced cost and high availability. More simply stated, managed care is the 
implementation of health insurance programs. There is a severe lack of managed care in 
the Appalachian region. Managed care rates are less than 15% in half of the states in the 
Appalachia region, and only four states have rates above 25%, which is still below the 
national average. Insurance plans are held by 75% of Appalachian children, significantly 
lower than the 85% of non-Appalachian children that possess insurance plans (“Child 
Well-being Survey”, 2011). Low rates of managed care in the region has a major impact 
on the healthcare of pediatric patients. Lack of insurance may lead to use of emergency 
room visits as the primary or source of healthcare. Parents that do not have insurance 
plans are less likely to have a primary care physician for their child, meaning the child 
will usually not participate in regularly scheduled appointments (Couto, 2012). Parents 
that do not have insurance plans are often low-income, which will have other 
implications to be discussed shortly. Lack of managed care will also lead restrictions on 
access to preventative and educational resources. Without managed care plans 
Appalachian children are less likely to receive care early on in life. They are also less 
likely to grow up attending regular appointments; this will likely carry over into adult 
life. The decreased levels of insurance plans is lessening the opportunities of healthcare 
for Appalachian children, and negatively impacting their health. 
        Low education levels in the Appalachian region may negatively impact the 
healthcare of pediatric patients in the region. In a consensus report in 2010 the ARC 
reported that 17.1% of the Appalachian population has no high school diploma, while in 
non-Appalachian regions, only 15% of residents do not have a high school diploma (“The 
Appalachian Region: A Data Overview from the 2006-2010 American Community 
Survey”, 2011). This statistic shows that Appalachians are not completing high school 
studies comparable to non-Appalachians, and thus will not continue on to receive 
secondary education. Uneducated populations are more likely to become ill and develop 
disease than educated populations. They are also less likely to notice and understand the 
severity when an illness arises, especially mental illness, and seek medical attention when 
needed (Turiano, 2014). Parents lacking education may not understand the complex 
medical terminology that is utilized to explain the health of their child and the importance 
of basic medical care, such as vaccinations and how to understand and read prescriptions. 
Part of this issue may arise from the social distance that is created among educated health 
professionals and uneducated patients. A language barrier often exists, leading to 
confusion on the patients’ end. This is partly due to an education gap between the health 
practitioner and the patient, but is also caused by the numerous doctors that are from 
outside Appalachia, who are unfamiliar with the colloquialisms of the region 
(Hutson,2007). The education gap and language barrier both add confusion to a parent, 
leading to hesitation when seeking care for their child. Uneducated parents are less likely 
to take their children to doctors’ appointments than more educated parents. This may be 
due to the fact that lack of education usually leads to career paths that do not produce a 
great income and lead to increased hours on the clock (Cutler, 2006). Many parents in the 
Appalachian region are working long hours to provide for their family and they do not 
have the time, resources, such as income and transportation, or the knowledge to 
understand general health and assure their child is receiving medical care on a scheduled 
basis. 
        Although it is impossible to define the social environment of Appalachian children 
as a whole, social trends can be determined to aid in understanding the health of 
Appalachian children.  The Child Well-Being Survey, conducted by the Cincinnati 
Children’s Hospital, reported that Appalachian children are more likely to live in single-
parent homes than non-Appalachian children (2011). Single-parent families may find 
difficulty in finding the time and resources to attend health appointments. Children in 
single-parent homes are likely to experience less health care than other children. Parents 
of Appalachian children are more likely to work full time and longer hours than parents 
outside the region (“Child Well-Being Survey”, 2011). Because of this, Appalachian 
children often possess part time caregivers. At a young age the children are watched by 
other family members, and are not socialized with children outside the family unit. The 
lack of a parental figure increases the independence in many Appalachian children, but 
often leads to increased behavioral issues and defiance. As a child matures, the absence 
of parental supervision increases the chances of alcohol and substance abuse (Couto, 
2012). Substance abuse is another issue that Appalachian children encounter often. 
Alcohol and drug abuse is extremely common in rural Appalachia, and often children 
mimic abuse behaviors they learn from observing parental actions. Sometimes parents 
even take advantage of access to their child’s medications, and the child does not  receive 
the medication they are prescribed (Zhang, 2008). The social environment of a child can 
lead to a decrease in the quality of the healthcare he receives. Providers should pay 
special attention to the social environment of the child, which revolves mainly around 
parental involvement and quality of care, and adjust interactions to account for the 
environment the child faces on a day to day basis.   











The Appalachian Region. (2015). Retrieved February 20, 2016, from  
http://www.arc.gov/appalachian_region/TheAppalachianRegion.asp  
The Appalachian Region: A Data Overview from the 2006-2010 American Community  
Survey. (2011). Retrieved February 23, 2016, from  
http://www.arc.gov/research/researchreportdetails.asp?REPORT_ID=96 
Behringer, B., & Friedell, G. H. (2006). Appalachia: where place matters in health. Prev 
 Chronic Dis, 3(4), A113. 
Child Well-Being Survey. (2011). Retrieved March 01, 2016, from  
http://www.cincinnatichildrens.org/service/j/anderson-center/health-policy/well- 
being/ 
Couto, R. A. (2012). Appalachian health and well-being. R. L. Ludke, & P. J. Obermiller 
 (Eds.). University Press of Kentucky. 
Cutler, D. M., & Lleras-Muney, A. (2006). Education and health: evaluating theories  
and evidence (No. w12352). National Bureau of Economic Research. 
Gessert, C., Waring, S., Bailey-Davis, L., Conway, P., Roberts, M., & VanWormer, J.  
(2015). Rural definition of health: a systematic literature review. BMC public  
health, 15(1), 1. 
Hutson, S. P., Dorgan, K. A., Phillips, A. N., & Behringer, B. (2007, November). The 
 mountains hold things in: the use of community research review work groups to  
address cancer disparities in Appalachia. In Oncology nursing forum (Vol. 34,  
No. 6, p. 1133). ONCOLOGY NURSING SOCIETY. 
Poverty Rates in Appalachia, 2009-2013 - Appalachian Regional Commission. (2014).  
Retrieved February 20, 2016, from 
http://www.arc.gov/research/MapsofAppalachia.asp?MAP_ID=114  
Puhl, R. M., & Heuer, C. A. (2010). Obesity stigma: important considerations for public 
 health. American journal of public health, 100(6), 1019-1028. 
Welch, W. (Ed.). (2014). Public health in Appalachia: Essays from the clinic and the  
field (Vol. 35). McFarland. 
Welch, W. (2011). Self control, fatalism, and health in Appalachia. Journal of  
Appalachian Studies, 108-122. 
Zhang, Z., Infante, A., Meit, M., English, N., Dunn, M., & Bowers, K. (2008). An  
analysis of mental health and substance abuse disparities & access to treatment  













ADHD in Appalachia and Tennessee 
       Cases of ADHD in the southern and Appalachian regions of the United States are 
rampant. The Appalachian region has high percentages of children diagnosed with 
ADHD between the ages of 4-17. Out of the 12 Appalachian states 7 had 13.1% or more 
parents report their child had been diagnosed with ADHD. The other 5 states had 11.1%-
13.0% of parents report a child with an ADHD diagnosis (Figure 1). The percentage of 
youth taking medication for ADHD is also high in the Appalachian region as a whole. 
Four of the 12 states have 5.1%-7.0% of youth taking ADHD medications, and another 4 
states have 7.1-9.0%. Of the 6 states in the US that have a 9.1% or greater youth 
population on ADHD medications, 2, Kentucky and North Carolina, are Appalachian 
states (Figure 2). It is clear through this data that the Appalachian region has a high 
amount of ADHD cases and it is important for further research to understand why it is so 
prevalent in these areas. 
         Tennessee has exceptionally high rates of diagnosed and medicated pediatric 
ADHD patients. According to the National Survey of Children’s Health conducted by the 
CDC in 2011, 15.2% of parents in Tennessee reported that a health care provider had told 
them their child had ADHD while the average in the U.S. was 11.0% of parents. 11.1% 
of parents in Tennessee reported their child currently has ADHD compared to an average 
of 8.8% in the US. The national average for pediatric patients taking medication for 
ADHD is 6.1%, and the report shows that 8.5% of Tennessee parents stated that their 
children were on medication for ADHD (State Profile: Tennessee, 2014). 
        Medications are also dispensed at a high rate in Tennessee, with little to no behavior 
management in place. In the same survey, when parents were asked if their child had 
taken ADHD medication in the past week, nationally 74% of parents reported their child 
had. 80% of Tennessee parents reported their child had taken ADHD medications in the 
past week; this placed Tennessee as the 12th highest state out of all states and D.C.. The 
survey also asked parents if their child had received behavior therapy, such as in class 
aid, peer counseling, or classroom management therapy, in the past year. Nationally 44% 
of parents reported their child had received behavior therapy. Only 33% of children in 
Tennessee had received behavior therapy; this was the lowest average nationally ranking 
Tennessee 51st out of all states and D.C. for patients receiving behavior therapy. Lastly 
the survey asked parents if their child had taken medication in the last week and received 
behavior therapy in the last year. The national average was 31%, and Tennessee was once 
again ranked 51st with an average of 22% (State Profile: ADHD, 2014). 
        These findings do not focus on the Appalachian region of Tennessee specifically, in 
which this study aims to focus on, but instead shows the data for the state as a whole. 
Very little data exists for Appalachian Tennessee health, and even less exists for mental 
health in Appalachia as a whole. However, this data does show that Tennessee overall has 
a high amount of ADHD patients and medication treatment. The data shows the 
importance of implementing more studies into ADHD in the Appalachian Tennessee 
region to combat this widespread disorder. Further studies should focus on why ADHD is 
a problem in Tennessee compared to other states and why medications are the preferred 
treatment method. This research project hopes to understand how factors in the 
Appalachian region lead to increased diagnosis and medication treatment for ADHD in 
pediatric patients throughout the region and specifically in the state of Tennessee. 
 
 
Figure 1. Percent of Youth 4-17 Ever Diagnosed with Attention-Deficit/Hyperactivity  
 Disorder by State: National Survey of Children's Health. Reprinted from Centers  
 for Disease Control and Prevention. Retrieved April 15, 2016, from  
 http://www.cdc.gov/ncbddd/adhd/prevalence.html 
 
Figure 2. Percent of Youth Aged 4-17 Years Currently Taking Medication for ADHD by  
 State: National Survey of Children's Health. Reprinted from Centers for Disease  
 Control and Prevention. Retrieved April 15, 2016, from,  
 http://www.cdc.gov/ncddd/adhd/medicated.html  
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Overview of ADHD 
         Attention Deficit Hyperactivity Disorder (ADHD) has likely been permeating 
society since the beginning of time, although it was not until 1998 that the United States 
recognized it as genuine medical condition (Moghadam, 2006). ADHD, often referred to 
by its former name Attention Deficit Disorder (ADD), is a complex mental and 
neurodevelopmental disorder that is often characterized by the inability to focus and 
avoid distractions appropriate to the age level of the person (Adler, 2015). Impulsiveness 
is also a common trait in ADHD patients, and this often leads to the inability to control 
temptations. ADHD was once viewed as a childhood illness, but is now seen as a disorder 
that can impact all age groups (McGough, 2014). While inattentiveness in a specific 
environment, such as church, school, or home, is a common element of childhood, 
children diagnosed with ADHD usually have difficulty with attentiveness in all 
environments (Moghadam, 2006). In recent years, focus on ADHD has increased and led 
to the development of a more accurate working definition. Medical professionals now 
recognize ADHD as a developmental disorder of the brain, instead of a strictly behavioral 
disorder (Brown, 2013). 
        As stated, ADHD is a severely complex disorder. No two patients exhibit the same 
complications and issues, and currently medical professionals are recognizing the 
importance of individuality in this condition. There are three forms of ADHD, 
inattentiveness, hyperactivity, and a combinational form. Patients can exhibit inattentive 
behavior with no hyperactivity, and others will exhibit hyperactivity but will still have the 
ability to focus on assignments they are interested in. ADHD patients with a combination 
of the first two forms will have an exceptionally difficult time focusing and managing 
restless behavior (Hinshaw, 2016). 
         Patients with ADHD suffer with two types of cognitive impairments: working 
memory and executive functions. Working memory is simply the ability to remember and 
act on several components at once. The ability to turn on the sink and remember why it 
was turned on is a fine example of working memory and how an individual might use it 
to complete simple daily tasks. The individuality of ADHD is mostly represented by the 
executive function impairment in the patient. Executive functions are the functions of the 
brain that plan, prioritize, strategize, and act. Lack of these functions may be why ADHD 
children arrive late to appointments, cannot keep track of assignments, and have social 
difficulty (Hinshaw, 2016). Lack of executive functions is not a lack of intelligence, but it 
does have everything to do with independence and self-care for ADHD patients. 
Executive functions may be impaired throughout a person’s life through head trauma 
accidents or Alzheimer’s, but ADHD patients have a developmental disorder of executive 
functions, meaning they simply never form. Some executive functions do develop and 
others do not, and that is why ADHD patients are so strikingly different and why 
treatment must start to cater to the individual’s needs and interests (Lezak, 2004). 
Causes of ADHD 
        The cause of ADHD has been debated since the illness was discovered. Over time 
the medical and scientific community has determined that the cause of ADHD is 
biological, however, social and environmental factors may fuel negative or positive 
effects of ADHD. The basic cause of ADHD comes down to a small neurotransmitter 
called dopamine. Dopamine travels across synapses in the brain, allowing the brain to 
decipher messages to produce functions. Too much dopamine can cause a manic state 
while too little can paralyze a person. Patients with ADHD either make too much of it or 
do not have enough receptors to use it efficiently. Norepinephrine is another 
neurotransmitter that is responsible for causing the impulsivity issues in patients with 
ADHD, however, dopamine is the more largely studied neurotransmitter (Hinshaw, 
2016). 
         While the above is the basic physiological cause of ADHD, many still wonder why 
this occurs.  This section of the introduction aims to discuss the biological causes and the 
social and environmental risks that may impact a patient with ADHD in a negative or 
positive manner. 
Genetics 
        Twenty to thirty percent of children diagnosed with ADHD have at least one other 
affected family member (McGough, 2014). There is no specific gene that is related to the 
inheritance of ADHD, but there may be as many as 50-100 alleles involved in influencing 
how the brain reads signals (Hinshaw, 2016). One of the most studied alleles is the 
DRD4-7 allele, which may cause the brain to develop fewer dopamine receptors. 
Dopamine is a neurotransmitter that causes excitement and stimulation. The lack of 
dopamine receptors causes the brain to feel tired and boredom to ensue, and in response 
the patient’s body begins to act fidgety and hyperactive to escape the lack of stimulation 
(Faraone, 2005). 
        While genetics may play a heavy role in the development of ADHD, there are 
several other factors that may influence how the patient responds to the condition.  
 
Prenatal and Perinatal Factors 
        While genetics and biology are the ultimate contributors to ADHD, other 
environmental and social factors are studied to see how they contribute. Prenatal refers to 
the time period of a fetus between conception and before birth, or during pregnancy. 
Perinatal refers to the time period a few weeks before birth, during birth, and a few weeks 
after birth. During the prenatal and perinatal time frame there are a number of events that 
may occur to increase ADHD-like symptoms (McGough, 2014). 
        Prenatal conditions including maternal cigarette consumption, lead, pesticides, and 
maternal alcohol abuse and dependence may aggravate ADHD symptoms (Brown, 2013). 
These conditions in prenatal and perinatal terms can have an effect on the already 
sensitive brain conditions of an ADHD patient (Hinshaw, 2016). Children with mothers 
that abused alcohol during pregnancy are twice as likely to develop ADHD, and children 
with mothers who are dependent on alcohol during pregnancy are three times as likely to 
develop ADHD like symptoms (Banerjee, 2007). It is important to note that many of the 
mothers in this study also had ADHD, so it is hard to tell whether the environment or 
genetics increased the risk of childhood ADHD development; many studies are trying to 
study which of the factors are playing a higher role (McGough, 2014).  
        Perinatal conditions such as toxemia, eclampsia, maternal age and health, and 
duration of labor may also play a role in increased ADHD risk (Brown, 2013). Halmoy, 
et al (2012) studied a population of adults with ADHD and proved that low birth weight 
and preterm birth increased the risk of ADHD and the lack of executive functions. 
Perinatal conditions are often associated with increased developmental disorders and that 
is why ADHD may appear more common in these births as it is a developmental disorder.   
Psychosocial Risks 
        Psychosocial refers to the interaction between social factors and thought and 
behavior. A famous study by Rutter, et al. (1975) stated that there are six factors that are 
associated with increased risk of psychiatric disabilities with pediatric patients: marital 
discord, low social status, large family size, paternal criminality, maternal mental 
disorder, and foster placement. It is important to emphasize that social factors do not 
cause ADHD, however, they play a role in how severe the condition becomes and how 
well the patient develops (McGough, 2014). Typically, the presence of one of these 
factors will not increase the severity of the condition, but the accumulation of two or 
more factors usually results in an increased negative effect on the pediatric ADHD 
patient (Rutter, 1975). 
        “Authoritative parenting” is a combination of firm consequences, warmth, 
independence, and guidance. ADHD patients that are under this kind of parenting thrive 
the best. Children that live in the above mentioned conditions are often not in a 
environment where authoritative parenting is practiced, and that is why the conditions 
listed in Rutter et al. (1975) are the most common for negative impacts in ADHD 
children. Parents that are arguing with the child or others, are not active in the child’s life, 
and are not focused on the needs of the condition are more likely to lead to the increase of 
the child’s symptoms (Hinshaw, 2016). While social status is not a cause of ADHD, it is 
definitely a strong indicator of the success the patient will have in combating the 
disability.       
 
    
Environmental Risks 
        Environmental factors that may contribute to ADHD are very broad. Some of the 
most controversial factors include lead in water, academic settings, and diet.  
        Lead in water has often been associated with ADHD symptoms, however not all 
patients with ADHD have been exposed to lead and only a small amount of patients that 
have been exposed to lead have ADHD. Patients that have been exposed to lead usually 
have other risk factors associated with ADHD including low socio-economic status, low 
paternal education levels, and poverty. Studies are continuing in this area (Nigg, J.T, 
2010). 
        Many people promote the belief that diet has an effect on causing or and promoting 
symptoms of ADHD.  There have been many studies revolving around sugar intake and 
ADHD, and none have concluded any significant correlation between the two (Bader, 
2012). Caffeine is another food component that may increase the attention in ADHD 
patients; there are no negligible effects (Leon, 2000). The only component in foods that 
has been proven to have an effect on ADHD patients is food coloring, especially Yellow 
No. 5. However, it has not been proven if specific characteristics and genotypes in a 
person are necessary for food coloring to have an effect on (Nigg, 2012). The studies 
involved in diet and ADHD have only been conducted with small samples in certain 
areas; further testing is necessary to confirm a precise conclusion. 
Gene-Environmental Interactions and Risks 
        Gene-environmental interactions are offered by an integrated viewpoint that has 
emerged with hopes to portray how the environment has an effect on increasing the 
symptoms of ADHD that are caused by biology. In this perspective biology causes 
ADHD and the environment fuels or depresses the disorder (Nigg, J., 2010). Some 
proponents of this interaction believe that adversity in the environment triggers the genes 
in a patient to firmly express ADHD characteristics (McGough, 2014). 
         Several studies discuss how food additives, such as colors, may only increase risk 
for patients that have or do no have certain genes. Similarly, studies have shown that 
maternal smoking only increases ADHD risk when certain alleles are present (Farone, 
2010). These are just a few examples of how the environment-gene model works in 
application with ADHD patients.  
Diagnosis and Assessment of ADHD in Children 
         ADHD is a clinically diagnosed disorder. The diagnostic criteria for ADHD is out 
in detail in the Diagnostic and Statistical Manual for Mental Disorders (fifth edition, 
DSM-5). The DSM-5 is the appropriate guide that physicians should consult during 
diagnosis of a mental disorder such as ADHD.The DSM-5 focuses on diagnosis through 
evaluation and assessment of the age appropriateness of inattention, hyperactivity, and 
impulsivity (McGough, 2014). 
        The DSM-II viewed ADHD as a hyperkinetic disorder that usually vanished by 
adolescence. The DSM-III was the first DSM to list a set of symptoms as a guideline 
broken up into hyperactivity, inattention, and impulsivity; in order to be diagnosed with 
ADHD a child must have had three of five inattention symptoms, three of six impulsive 
symptoms, and two of six hyperactive symptoms (McGough, 2014). The DMS-IV 
introduced 18 symptoms, 9 inattentive and 9 hyperactive/inattentive. 
         The DSM-5 is the current manual that physicians use to diagnose a patient with 
ADHD. There have been several changes to the DSM-5 from the DSM-IV. First of all, 
ADHD is no longer listed as a disruptive behavioral disorder, showing the changing view 
of the disorder. While the DSM-IV states that symptoms must show by age seven, the 
DSM-5 states that the symptoms may show as late as age twelve. Other changes of note 
includes wording to promote the fluidity of the disorder, changes in subtypes of ADHD, 
and impairment is no longer a necessity for diagnosis (Adler, 2015).  
        The DSM-5 retains the 18 symptoms in the DSM-IV (Table 1). According to the 
DSM-5, a patient must exhibit 6 of the 9 symptoms for inattention (Table 1) and/or 6 of 
the 9 symptoms for hyperactivity-impulsivity (Table 2) for pediatric patients 16 and 
under, and 5 of the 9 for one or both groups if 17 and older (McGough, 2014). In addition 
to the symptom conditions, the condition must have an onset before age 12, the 
symptoms must be present in two or more settings, the symptoms must have a clear 
impact on the function of the individual, and the symptoms must not be better explained 
by another mental disorder (Adler, 2015). 
        A child is usually assessed by a medical professional if ADHD is suspected. Usually 
children exhibit symptoms during preschool or early grade school. Often teachers are the 
first ones to notice ADHD- like symptoms and recommend treatment be sought. If 
children do not exhibit ADHD signs and symptoms by elementary, they should by middle 
school due to the increase in workload and their inability to focus on the tasks in class. 
Most often, parents take their children to pediatricians to be diagnosed, most of which are 
not trained in mental illness and are quick to prescribe prescription drugs before behavior 
therapy (Hinshaw, 2016).  
         A critical part in diagnosing pediatric ADHD patients is the involvement of all or 
most systems the child is involved in. Usually the child, parent(s), teacher(s), and other 
third parties such as coaches are involved in providing information to the medical 
professional assigned to the case, allowing the doctor to make an informed decision. 
Before an assessment is scheduled the doctor usually sends out questionnaires, in the 
form of rating scales, for everyone to rate the performance of the child for specific tasks 
(McGough, 2014). These questions will provide the best insight for the physician to make 
a correct diagnosis, however it is important that he take care if the questionnaires differ in 
opinion. Parents, teachers, and other parties may have bias;for example, a teacher may 
prefer ADHD medications for a child, simply to improve classroom grades (Nass, 2005). 
         On the day of the assessment a medical professional meets with the child and 
usually the parents. The sad truth is that most of these visits last 10-15 minutes, where the 
physician analyzes the data, makes a diagnosis, and then prescribes medication or other 
treatment. The assessments from third parties are collected and the physician takes time 
to interview the parents and the child more thoroughly according to the DSM-5 
guidelines. Sometimes doctors have computerized or physical behavioral tests in place to 
observe the actions of the child.  A medical assessment is done in this visit as well, even 
if a non-medical professional is conducting the diagnosis. A basic health physical is 
conducted, family information is collected, and previous medical history is taken as well. 
These procedures are set in place due to the high risk of cardiovascular issues and risks 
that arise when a pediatric patient is placed on stimulant medications for ADHD 
(McGough, 2014). 
Planning of treatment 
        Treatment plans for ADHD patients are specific and focus on the individual needs of 
the patients. The optimal treatment for pediatric ADHD patients is a combination of 
medications behavior and family therapy and counseling, and classroom management. 
ADHD medications were originally introduced for use only when behavior management 
fails or needs a supplement (Moghadam, 2006). The famous Multimodal Treatment 
Study of ADHD (MTA) proved that medications lessened symptoms of ADHD but did 
not improve functionality quality of the patient like behavior therapy and counseling did 
(Murphy,2005). The emphasis of this paper is to focus on prescription medication use in 
the Appalachian region as it pertains to ADHD patients, however a discussion of 
alternative therapies is necessary to understanding all of the therapy options that can be 
utilized in addition to medications in the Appalachian area. 
        When a doctor is deciding the correct treatment plan for a ADHD child, the severity 
of the case and the individual needs of the patient are deciding factors. Treatment of 
ADHD is a very personal plan and no two patients are the same. Most experts agree that 
pharmacotherapy should only be considered in cases where behavior therapy cannot be 
the only source of treatment. However, most patients are placed on medications of some 
kind. The type of medication selected should be based on severity, age, comorbidities, 
and reception of medication. It is common for medication to be a go to source of 
treatment, however no physician should ever believe that medication treatment should be 
the only source of treatment in pediatric patients (McGough, 2014). All patients and 
guardians should be in constant contact with a physician and school personnel to monitor 
treatment and behavior no matter the treatment plan. 
          Family focused interventions include parent and child therapy counseling sessions. 
These sessions aim to eliminate barriers to effective parenting. This type of counseling is 
beneficial to those that are facing stressors in the family home. These sessions are 
organized into 1-2 sessions for an hour or two a week, and they can be in multiple 
settings, individually or in groups.  The counselor focuses on teaching the parents how to 
care for a child with ADHD, and emphasis is placed on relationships, structure, 
consistency, and health (Forehand, 2013). A more specific type of family intervention is 
called parent child interaction training (PCIT). This type of counseling focuses on 
teaching parents with younger ADHD patients how to build lasting relationships early on  
in the child’s life (Charach, 2013). 
          Another method of behavior therapy for ADHD patients is school-focused 
interventions. Management of ADHD should be carried over into the classroom through 
proper classroom placement. The Federal Rehabilitation Act of 1973 states in section 504 
that students with mental or physical limitations can receive modifications in the 
classroom such as preferred seating and extended times on tests to accommodate for the 
disability (Semrud-Clikeman, 2011). Usually 504 modifications are only given to severe 
ADHD patients, as a diagnosis alone is not sufficient to gain 504 plans until extensive 
counseling is completed and the school approves. Most ADHD students can gain 
behavioral classroom management, which is similar to the home intervention in style and 
content. This type of management depends on the cooperation of the teacher. Most plans 
utilize daily report cards and appropriate consequences and limitations in the child’s daily 
routine (Pelham, 2008). 
           








Table 1.  Inattentive Symptoms of ADHD described in the DSM-5 for diagnostic 
     purposes 
 





Table 2. Hyperactive/impulsive behavior Symptoms of ADHD described in the DSM-5 
for diagnostic purposes 
 









1 Often fails to give close attention to details or makes careless mistakes in 
schoolwork, at work, or with other activities. 
2 Often has trouble holding attention on tasks or play activities. 
3 Often does not seem to listen when spoken to directly 
4 Often does not follow through on instructions and fails to finish schoolwork, 
chores, or duties in the workplace (e.g., loses focus, side-tracked). 
5 Often has trouble organizing tasks and activities. 
6 Often avoids, dislikes, or is reluctant to do tasks that require mental effort over a 
long period of time (such as schoolwork or homework). 
7 Often loses things necessary for tasks and activities (e.g. school materials, 
pencils, books, tools, wallets, keys, paperwork, eyeglasses, mobile telephones). 
8 Is often easily distracted 
9 Is often forgetful in daily activities. 
1 Often fidgets with or taps hands or feet, or squirms in seat. 
2 Often leaves seat in situations when remaining seated is expected. 
3 Often runs about or climbs in situations where it is not appropriate (adolescents 
or adults may be limited to feeling restless). 
4 Often unable to play or take part in leisure activities quietly. 
5 Is often "on the go" acting as if "driven by a motor" 
 
6 Often talks excessively. 
7 Often blurts out an answer before a question has been completed 
8 Often has trouble waiting his/her turn. 
9 Often interrupts or intrudes on others (e.g., butts into conversations or games) 
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Overview of ADHD Medications in Pediatric Patients 
Stimulant Medications 
        Psychostimulant medications are the most effective type of medication prescribed to 
ADHD patients (Adler, 2015). In fact, 70% of ADHD patients taking stimulants, respond 
and prefer stimulant medication to other forms of ADHD treatment (McGough, 2014).  
Psychostimulants are psychopharmacological agents used to enhance behavioral and 
cognitive functions by stimulating the central nervous system (CNS). Most stimulants are 
called “amphetamine-like agents” because they are similar to dopamine and 
noradrenaline, two neurotransmitters that contain amine groups (Gerlach, 2014). While 
there are several types of stimulant medications available, there are two main 
classifications of stimulants in ADHD treatment; methylphenidates and amphetamines. 
        In order to understand the physiological mechanism behind psychostimulants, one 
must understand basic nervous system anatomy and physiology. The central nervous 
system is composed of the brain and the spinal cord. The brain and the spinal cord are 
made of neurons, or nerve cells. A neuron has a cell body, which contains mostly 
cytoplasm and neurotransmitters, an axon, which is an elongated area of the cell which 
transports signals to and from the neuron cell body, and dendrites, which serve to sense 
the environment and tell the cell body to produce a signal along the axon to other 
neurons. An electrical signal is transported along the axons of neurons to the brain where 
the signal leads to a response. Signals are passed from neuron to neuron through a 
structure called a synapse. Most synapse structures are formed where the end of one 
neuron’s axon and the dendrites of another neuron meet. Chemical messengers, called 
neurotransmitters, are released into the synapse by the pre-synaptic neuron and received 
by the post-synaptic neuron allowing the signal to continue. There are several types of 
neurotransmitters, but some commonly known ones include dopamine, norepinephrine, 
and epinephrine. 
         There are several adverse effects that may occur with the use of stimulant 
medication. The most common effect is loss of appetite, but other effects include 
dizziness, nausea, dry mouth, tics, and cardiovascular issues (McGough, 2014). The use 
of stimulant medication neither increases nor decreases the likelihood of abuse (Wilens, 
2003). Stimulants are most likely to be abused by college students to increase cognitive 
abilities, not pleasure; 5% of college students have reported abuse of stimulants 
(McCabe, 2005).   
Methylphenidates 
        Methylphenidates(MPH) were first produced in 1944 as a lethargy and depression 
drug. Currently they are one of the most common drugs prescribed for ADHD patients 
(Barceloux, 2012).  MPHs are psychostimulants and act upon the central nervous system 
to increase activity in the prefrontal cortex of the brain, which is associated with 
regulating attention, behavior, and cognition. There is one main mechanism of action 
associated with MPHs.  In the neurological synapse of neurons in the brain, there are 
transporters that release and take up neurotransmitters from the synapse. One of these 
transporters is the dopamine transporter (DAT), a transporter that reuptakes dopamine 
from the synapse into the cytosol of the neuron. When MPHs enter the synapse, they 
compete with dopamine for binding onto DATs. This creates competition and because 
MPHs have a higher affinity to the DATs, dopamine reuptake is inhibited. This creates a 
high concentration of dopamine in the synaptic cleft. The increase of dopamine in the 
synapse creates an increase in dopaminergic neurotransmission increasing the activity in 
the prefrontal cortex of the brain (Barceloux, 2012). This, in turn, promotes increased 
focus and good behavior in ADHD patients. 
        Methylphenidates are prescribed as tablets, chewable tablets, and oral solutions. 
Most commonly MPHs are prescribed as immediate effect dosages, meaning the effects 
will be seen at greatest capacity within 3-5 hours. There are extended release (ER) MPHs 
as well, that can provide a lasting effect for 10-12 hours after taken. In addition to 
common tablets, there are beaded preparations that allow a parent to sprinkle the beads 
over a child’s food for ingestion (Adler, 2015). The FDA recommends a maximum dose 
of 60 mg/day for immediate release forms and 72 mg/day for ER forms. First time 
patients usually begin on a low dosage of 2.5mg to 5mg and then brought up to a target 
dose of 0.6 to 2 mg/kg.  For pediatric patients it is recommended that medication only be 
taken once daily, usually in the morning, but this can vary based on social and academic 
needs (Pliszka, 2007). Pediatric patients must also be evaluated frequently for dosage 
changes. Many times children are placed on more abrasive medications, when the issue is 
they have outgrown the recommended dosage for their weight. Methylphenidates have a 
low tolerance and often require a high dosage adjustment (Wilens, 2005). There are 
several MPH brand name drugs available including Ritalin, Concerta, Metadate ER, 
Methylin, and Daytrana. The only differences amongst these are the names, dosage, and 
release mechanisms (Adler, 2015).  
Amphetamines 
       Amphetamines (AMPHs) have been around for hundreds of years. It was not until 
the 20th Century that amphetamines became commercially available and popularity 
spread. In 1929 biochemist Gordon Alles developed a formula for amphetamine. He 
utilized his formula to develop a Benzedrine Inhaler for congestion. The inhaler was 
widely popular, but in 1959 the FDA required a prescription for sale due to mounting 
abuse (Adamec, 2011).  Amphetamines are widely popular drugs for treating symptoms 
of ADHD. The chemical structure of AMPHs varies, which is why there are several 
variants. AMPHs have a general chemical structure of a phenethylamine core with 
methyl groups in the alpha position. Substitutions of the groups on the phenyl core is 
what creates many types of AMPHs, and often there is a mixture of AMPHs in an ADHD 
medication (Rincon, 2012) AMPHs are a group of psychostimulants that act on the 
central nervous system. They increase the amount of dopamine, norepinephrine, and 
serotonin in the brain.  They have a similar mechanism of action to MPHs and act by 
inhibiting monoamine transporters such as DAT, serotonin transporters, and 
norepinephrine transporters. (Rincon, 2012) 
        Amphetamines are prescribed in tablet and capsule forms. They are considered a 
Schedule II drug due to the high risk of abuse and addiction. The absorption of AMPHs is 
usually rapid with a peak plasma level usually seen three hours after the medication is 
taken (Patrick).  There are forms of AMPHs in ER form prolonging the effects of the 
medications and creating a peak blood plasma concentration after seven hours after 
taking the medication (Millichap, 2011). However, it is not recommended to prescribe 
ER and long lasting AMPHs to children under the age of six (Gerlach, 2014). For first 
time patients, a low dose of 2.5mg to 5mg is started and then brought up to 0.3 to 1 
mg/kg a day. As stated above with MPHs, a single daily dose is recommended, but 
multiple doses can be administered up to 40mg a day.  There are several AMPH brand 
name drugs available including Adderall and Adderall XR (mixed amphetamines and 
dextroamphetamines), Dexedrine and Spansule (D-amphetamines), Vyvanse 
(Lisdexamphetamine dimesylate), and Desoxyn (D-methamphetamine). 
   
 Non-Stimulant Medications 
        Non-stimulant medications are prescribed to pediatric ADHD patients as a second or 
third line drug. If stimulants appear to produce comorbidities, if a risk of abuse is present, 
or if a response is not seen, non-stimulant medications may be used as a monotherapy or 
combined with stimulants to produce a more refined response (Adler, 2015). While non-
stimulants are generally not as effective, many patients do report increased attention 
spans. There are two main types of non-stimulant medications that are prescribed to 
pediatric ADHD patients, norepinephrine reuptake inhibitors and alpha-2 agonists. 
Norepinephrine Reuptake Inhibitors 
        Norepinephrine reuptake inhibitors (NRIs) are a class of drugs that act on the 
norepinephrine transporter in the prefrontal cortex of the brain. NRIs are second line 
drugs in the treatment of ADHD. They are prescribed when the patient experiences 
comorbid tics and, or abuse. NRIs prevent the reuptake of NE into the synapse, thus 
increasing the concentration in the synaptic cleft allowing for more connections and 
increased focus and behavior (Gerlach, 2014). While MPHs bind better to DATs, NRIs 
do not affect the dopaminergic pathway. Because there is not much dopamine present, the 
potential for abuse is low since high dopamine levels trigger the reward system of the 
brain promoting abuse (Gozal, 2005).  
        Norepinephrine reuptake inhibitors are prescribed in tablet and capsule forms 
mainly. They are not considered a Schedule II drug since the potential for abuse is low. 
The absorption of NRIs is rapid with a peak plasma concentration level occurring 1-2 
hours after taking the medications. The dosage is weight dependent. Most pediatric 
patients start at a dose of 0.5mg/kg/ day for the first week, and then work up to the target 
dose of 1.2mg/kg/day (Adler, 2015). It is recommended to give the medication with food 
to offset nausea, if necessary. Also, if drowsiness occurs, it is suggested to give the 
medication at night (Gerlach, 2014). One of the most popular NRIs is Strattera, or generic 
Atomoxetine (ATMX). Strattera is available in capsules of 10,18, 25,40, 60, and 100 mg 
(Adler, 2015).  
        Overall, NRIs are slightly less effective than MPH (Newcorn, 2008), and are 
significantly less effective than AMPHs (Wigal, 2005). NRIs should still be considered a 
first line drug for patients who suffer from adverse effects of stimulants(Wigal, 2005). 
Improvement is generally seen starting around 4 weeks after NRIs are started in a patient, 
with the full effects displayed in 6-8 weeks. There are several potential adverse effects 
such as insomnia, irritability, mood swings, and suicidal thoughts (Adler, 2015). 
Alpha-2 Agonists 
        Alpha-2 agonists are the second main type of non-stimulant medication used to 
combat ADHD. Like NRIs, alpha-2 agonists are considered a second line drug for normal 
ADHD patients, but a first line drug for ADHD patients that experience abuse and 
comorbid tics. Alpha-2 agonists were originally developed as antihypertensive 
medications, and thus are given to patients that may have high blood pressure as well 
(Millichap, 2011).  
        An adrenergic alpha- agonist is an agent that stimulates the alpha adrenergic 
receptors. Adrenergic receptors are receptors that receive signals from neurotransmitters 
such as norepinephrine and epinephrine, and then signal to produce a response. The 
binding of norepinephrine or epinephrine will usually trigger a flight-or-fight response. 
There are  two subtypes of adrenergic receptors, alpha and beta. The alpha subtype is 
broken down into two more types, alpha-1 and alpha-2. While alpha-1 receptors are 
found in smooth tissue, alpha-2 receptors are mostly found in the pancreas and 
neurological synapses. Alpha-2 receptors, when stimulated with norepinephrine and 
epinephrine, will inhibit the release of more norepinephrine and epinephrine through a 
mechanism called feedback inhibition(Sinclair, 2003). Alpha-2 agonists mimic the 
actions of norepinephrine and epinephrine and fool the body into thinking the levels are 
actually higher than they really are. The body then decreases the amount of 
norepinephrine and epinephrine released into synapses, thus creating the sedative effects 
that alpha-2 agonists are associated with (Bidwell, 2010). It might seem strange that a 
sedative effect would improve ADHD symptoms for a patient. The exact mechanism in 
which alpha-2 agonists aid ADHD patients is not fully understood, but it is believed that 
low levels of norepinephrine and epinephrine caused by the agonists have a calming and 
sedative effect on patients, providing them with improved focus and less hyperactivity 
(Banaschewski, 2004). 
        One type of alpha-2 agonist is clonidine. Clonidine is manufactured in two main 
forms, immediate release (CIR) and extended release (CXR). The immediate release form 
only has an effect for three to six hours, while the extended release form is released over 
a twelve hour period. The extended release form of clonidine has been proven to lessen 
the possibility of adverse effects. CIR is made in 0.1, 0.2, and 0.3mg tablets and CXR is 
made in 0.1 or 0.2mg tablets (Adler,2015). Pediatric patients are most often prescribed 
CXR, as the CIR is associated with adverse effects such as dry mouth and increased 
sedation. Patients are started on a smaller dose of 0.1mg/day at bedtime, and then brought 
up to a target dosage around 0.2mg/ day (Gerlach, 2014). Improvement for patients 
utilizing this drug is usually seen two weeks after the medication is begun (Jain, 2011). 
Clonidine has been proven as an effective drug in several studies (Jain, 2011) and is also 
proven to be effective as an adjunctive treatment with stimulant medications (Kollins, 
2011). There are several adverse effects that may occur when taking this medication. 
Increased fatigue and sedation, headaches, dizziness, dehydration, dry mouth, and blood 
pressure oscillations are just a few of the risks (Adler, 2015). Patients should not stop 
taking clonidine abruptly due to the possibility of blood pressure elevation, headaches 
and tics. If a patient needs to stop taking clonidine, a gradual weaning over 4-7 days 
should occur (Millichap, 2011). 
        Another alpha-2 agonist used to treat ADHD is guanfacine. The main difference 
between guanfacine and clonidine is that guanfacine is more specific for alpha-2A 
receptor subtype (Gerlach, 2014). Guanfacine is also less potent than clonidine, however 
this is accounted for in the dosage (Adler, 2015). Guanfacine is also manufactured in 
immediate and extended release forms, and the two are not interchangeable. GIR is made 
in 1 and 2mg tablets and GXR is made in 1,2,3, and 4 mg tablets. Pediatric patients are  
usually given GXR and are started on a dose of 1mg/day. This is increased gradually up 
to 4mg/ day (Gerlach, 2014). Improvement is usually seen in patients between two and 
four weeks after treatment is started (Jain, 2011). Guanfacine is generally effective in 
treating hypertensive pediatric patients, although it is still significantly less effective than 
MPHs. It is also proven to be more effective for some patients when guanfacine is used in 
conjunction with MPHs (Spencer, 2009).  The adverse effects are similar to clonidine, 
and include cardiovascular problems, dry mouth, dizziness, and sedation, although dry 
mouth and sedation are usually less likely with guanfacine. Just like clonidine, 
guanfacine should not be suddenly discontinued, as withdrawal and cardiovascular 
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Limitations, Proposed Methods, and Expected Results. 
         Several limitations occurred that prevented this study from being a complete report. 
The inability to gain access to de-identified personal health information from a local 
pharmacy was the main limitation. A lack of response created a situation in which the 
research could not be completed. The goals of this study will be outlined in detail so that 
they may be completed at a later time.  
         First, de-identified PHI for pediatric patients on ADHD medication was to be 
collected from a local independent pharmacy that had three separate locations in vastly 
different areas of town. A whole year of PHI would have been requested for all patients 
from each location that are prescribed any of the stimulant and non-stimulant ADHD 
medications discussed in prior sections. The PHI would have been de-identified before 
collection. The PHI ideally would have replaced the patient’s name with a number in a 
manner that the patient could not be re-identified. In addition to the patient’s name, 
address, prescribers, and any additional medical information could not be accessed. The 
only information included on the PHI would have been the medication name, number of 
scripts written for that medication, the number of times the medication was received by 
the patient, and the dates the medication was received. If possible, the birthday of the 
patient would have been collected so that age of the pediatric patient could be included in 
data analysis. 
         As stated, the pharmacies were located in three different areas of town. After PHI 
collection, analysis of each of the pharmacy locations would have occurred. Several 
websites are available for this information. The Appalachian Regional Commission has 
data available for personal income, education, unemployment, and poverty for each 
county and state in the Appalachian region, including Tennessee and Knox County. In 
addition, the Center for Disease Control (CDC) also offers many data sheets specifically 
for ADHD. These sheets show data for medication and treatment plans for ADHD 
patients in the state of Tennessee as a whole and by region.  
        The preferred website for use in this study comes from the Online Analysis and 
Statistical Information System. This is a website devoted to showing health statistics for 
specific regions. The Social Impact Mapper is an interactive map that shows 
socioeconomic status and demographics for neighborhoods. It is designed to be used to 
highlight health disparities and issues. This interactive map allows users the ability to 
select certain demographics and ranges and the site will highlight the regions that meet 
the specifications made by the user. Demographics can be changed so that income, 
poverty, education, single parent household percentages, age, race, and gender can be 
shown for a specific range. For example, if a user wants to choose an area with a low 
income, an income range can be selected and the map will highlight areas that have a low 
income in the range selected.  
       These resources would have been used to collect information including race, gender, 
income level, education levels, and poverty, among others, for the people living in 
neighborhoods surrounding the three pharmacy locations. Information about schools and 
health institutions in the area surrounding each pharmacy would have also been collected. 
This data would have then been compared to the PHI data with the purpose to show any 
correlations between the demographics of the pharmacy location and the patients at that 
pharmacy. Because each pharmacy was in a different area of Knoxville, it was expected 
that each location would have a significant difference in patients and demographics of the 
area. Results may have shown that specific demographics correlate to trends in ADHD 
medication usage and prescriptions. 
        Several assumptions would have been made with this approach, including one that 
the patients receiving medication from the pharmacy presumably should live in the area 
around the pharmacy’s location. Also, it assumes that the patient is in a certain socio-
economic status based on the location of the pharmacy and the neighborhoods 
surrounding it. In addition, it assumes that the patients coming to the pharmacies in the 
study are representative of the whole Knoxville population. Lastly, the study does not 
take into account any personal reasoning behind receiving medications and alternative 
therapy the patient may be receiving. These assumptions were made based on the nature 
of the de-identified PHI. If this study were to be completed in a widespread manner, more 
than three pharmacies should be included to assure that the entire population of Knoxville 
is accounted for. Also, approval should be sought for a study that may include more 
patient information to assure that the patient is associated with correct demographics. 
Perhaps funding and approval should be gained so that large retail pharmacies that are 
located in more areas throughout town may be able to participate. 
        This study hoped to find a correlation between ADHD patients, their medication, 
and certain demographics such as race, socio-economic status, income level, and 
education among others. It also aimed to show trends in ADHD medication reception 
over a typical year so that medications given during time in school and time out of school 
could be analyzed. The data provided could then be used to create plans for enhancing 
ADHD patient diagnosis, treatment, and medication therapy management. 
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        In the United States 3%-10% of children have been diagnosed with Attention Deficit 
Hyperactive Disorder (McGough, 2014). Western states have a significantly lower rate of 
ADHD diagnoses than southern and Midwest states. Many southern states have rates of 
ADHD diagnoses as high as 15% or greater. The same is true for rates of medication for 
pediatric patients. An ADHD patient in the south is twice as likely as an ADHD patient in 
California to receive medication for ADHD (Hinshaw, 2016). Many of the southern states 
that have high rates of diagnoses and medication rates are Appalachian states, and the 
state of Tennessee is referenced often as having some of the highest rates of ADHD 
diagnoses in the country. 
        It is apparent that ADHD has been embraced by the medical community, and thus is 
becoming a burden to society, especially in southern Appalachian states. The question 
still is why many of the Appalachian states are suffering with the burden of ADHD more 
than other states. While studies have shown ADHD is caused by biological sources, the 
severity of the disorder often has a lot to do with the social and economic environment 
the child is placed in. The Appalachian certainly has a unique culture, socially and 
economically, that may contribute to the high rates of diagnoses and medication therapies 
being received. 
        It is important to consider all of the possibilities that may factor into a child being 
diagnosed and receiving medications for ADHD. The Appalachian region has many 
factors such as school systems with a high focus on testing scores, high unemployment, 
poverty, high rates of single parents, and low access to medical care and coverage that 
may affect how ADHD is perceived and diagnosed. This study hoped to be able to look at 
various social factors in different regions of an Appalachian town to try and uncover the 
social and economic factors that create trends in ADHD medications in an Appalachian 
town. Unfortunately, limitations prohibited the completion of the study.  
          ADHD causes a significant burden on the family system as well as educational and 
social systems in a ADHD child’s life. Children that have ADHD are more likely to 
struggle in school, have other mental disorders in addition to ADHD, and have issues 
later in life with gambling, criminal activity, and substance abuse (Kessler, 2006). ADHD 
children are also more likely to experience increased emergency room visits and 
accidents (McGough, 2014). ADHD can cause an extreme burden on a family that is 
lacking an education and steady income to afford sufficient treatment and therapy. Many 
Appalachian families are not educated enough to understand the various treatment 
options and how to manage a child that has ADHD at home and at school. In addition on 
average an ADHD pediatric patient’s parents spend $1,000-$5,000 in medical expenses 
for appointments and treatment (Doshi, 2012). 
        ADHD research is necessary in the Appalachian region for a number of reasons. The 
high costs associated with having an ADHD family member, creates a financial burden 
on a struggling economic region. Medical costs for a pediatric ADHD patient are three 
times more than an average child annually. Pediatric patients that do not manage their 
condition mature into adults with ADHD, and usually struggle to maintain employment 
to afford treatment (Biederman, 2006). Decreasing the number of ADHD patients in the 
region, or even defining treatment to include less expensive medications, would reduce 
the cost for many families and create more successful, productive citizens in the 
community. Also, gaining support from school systems would be beneficial in creating 
curriculums to stimulate the minds of children that struggle with ADHD symptoms; this 
may also aid in decreasing the number of failing schools in the Appalachian region. 
ADHD patients are at risk for greater criminal activity. Pediatric ADHD patients will on 
average spend more time on probation and have higher criminal convictions (Olazagast, 
2012). Acknowledging medication trends and crafting behavior therapy plans to 
accompany or replace them should be the goals of physicians and pharmacists to decrease 
the counts of criminal activity from ADHD patients. It is important to discuss why 
ADHD is a problem in the Appalachian region as discussions could promote increasing 
educational efficiency, decreasing criminal behaviors, and relieving financial burden on 
families and the community. 
        There is a correlation between ADHD cases and many of the specific social burdens 
that Appalachian families experience such as low income, low education levels, 
unemployment, and family culture. It is apparent through research and statistics that 
ADHD is a problem in the Appalachian region, and the high rates may be caused by the 
social and economic issues stemming from the region. Understanding the social factors 
that may be causing high trends in ADHD medication treatment and diagnoses in the 
Appalachian region is key to developing a medical plan and educational materials to aid 
the families financially, emotionally, and physically. It is important to understand that 
ADHD patients also have many comorbidities, and through research it may be possible to 
focus on behavior therapy rather than medication so that individuals receive a well-
rounded treatment that is not set on specific standards. Perhaps, the solution should be to 
combat the issues that Appalachian families face, such as poverty and low education, 
instead of fighting the high ADHD case rate. It might be that if the social issues of the 
Appalachian region were aided then ADHD rates may decrease. However, further 
research is necessary to determining an exact cause. By analyzing the areas that are 
receiving  medication and treatment at a high rate, society can begin to combat the issues 
and give aid to groups that need it, so ADHD will not become a societal burden to the 
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